STATE STREET CORP - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$74,101,956
-14.2%
10,466,378
-14.7%
0.00%
-20.0%
Q2 2023$86,338,342
-9.1%
12,263,969
+7.7%
0.01%0.0%
Q1 2023$94,989,576
-62.8%
11,389,623
-48.8%
0.01%
-37.5%
Q4 2022$255,472,728
+115.6%
22,253,722
+136.6%
0.01%
+14.3%
Q3 2022$118,494,000
+1.8%
9,404,247
-14.5%
0.01%0.0%
Q2 2022$116,431,000
-4.0%
11,004,803
+47.5%
0.01%
+16.7%
Q1 2022$121,344,000
+6.2%
7,462,752
-9.5%
0.01%
+20.0%
Q4 2021$114,249,000
+11.9%
8,249,029
+16.1%
0.01%0.0%
Q3 2021$102,103,000
+3.3%
7,105,323
+13.6%
0.01%0.0%
Q2 2021$98,856,000
+33.0%
6,252,772
-14.4%
0.01%
+25.0%
Q1 2021$74,331,000
-9.8%
7,308,816
-33.9%
0.00%
-20.0%
Q4 2020$82,374,000
+48.2%
11,056,979
-31.7%
0.01%
+25.0%
Q3 2020$55,592,000
-25.1%
16,183,973
+3.9%
0.00%
-20.0%
Q2 2020$74,231,000
+545.9%
15,578,395
+171.1%
0.01%
+400.0%
Q1 2020$11,492,000
-39.4%
5,746,052
+4.6%
0.00%0.0%
Q4 2019$18,951,000
+36.1%
5,492,943
+13.0%
0.00%0.0%
Q3 2019$13,929,000
-44.7%
4,861,776
-26.8%
0.00%
-50.0%
Q2 2019$25,187,000
-11.8%
6,645,717
+89.3%
0.00%0.0%
Q1 2019$28,572,000
+26.6%
3,510,042
+25.5%
0.00%0.0%
Q4 2018$22,571,000
-12.9%
2,796,960
-17.6%
0.00%0.0%
Q3 2018$25,909,000
+23.0%
3,395,701
-7.7%
0.00%0.0%
Q2 2018$21,072,000
-2.0%
3,677,404
-18.4%
0.00%0.0%
Q1 2018$21,494,000
+12.4%
4,504,714
+15.7%
0.00%0.0%
Q4 2017$19,120,000
+23.0%
3,894,547
+31.2%
0.00%
+100.0%
Q3 2017$15,545,000
-28.5%
2,967,585
-24.1%
0.00%
-50.0%
Q2 2017$21,736,000
+13.9%
3,909,013
+72.0%
0.00%0.0%
Q1 2017$19,083,000
+44.1%
2,272,104
+8.6%
0.00%
+100.0%
Q4 2016$13,246,000
+122.8%
2,092,888
+55.2%
0.00%0.0%
Q3 2016$5,945,000
+56.3%
1,348,308
+0.7%
0.00%
Q2 2016$3,803,000
+0.0%
1,339,348
-0.3%
0.00%
Q1 2016$3,802,000
-82.6%
1,343,332
-36.5%
0.00%
-100.0%
Q4 2015$21,823,000
-39.3%
2,114,768
-32.9%
0.00%
-50.0%
Q3 2015$35,938,000
-25.0%
3,152,313
-1.8%
0.00%
-20.0%
Q2 2015$47,927,000
+58.9%
3,210,208
-3.9%
0.01%
+66.7%
Q1 2015$30,171,000
-11.1%
3,341,212
+19.7%
0.00%0.0%
Q4 2014$33,933,000
+48.8%
2,790,435
+19.7%
0.00%
+50.0%
Q3 2014$22,811,000
-20.4%
2,332,066
+3.8%
0.00%
-33.3%
Q2 2014$28,653,000
+65.3%
2,247,454
+37.2%
0.00%
+50.0%
Q1 2014$17,334,000
+1124.2%
1,638,419
+121.2%
0.00%
Q4 2013$1,416,000
+296.6%
740,687
+1412.1%
0.00%
Q3 2013$357,000
+457.8%
48,984
+18.7%
0.00%
Q2 2013$64,00041,2840.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Burrage Capital Management LLC 864,916$13,674,00013.71%
Sarissa Capital Management LP 4,261,000$67,366,0005.36%
ORACLE INVESTMENT MANAGEMENT INC 1,920,733$30,367,0004.18%
HealthCor Management, L.P. 3,248,100$51,352,0002.05%
Parkman Healthcare Partners LLC 351,961$5,565,0001.22%
Bain Capital Public Equity Management II, LLC 1,560,730$24,675,0001.06%
Baker Brothers Advisors 12,710,818$200,958,0000.88%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,835,000$44,821,0000.80%
Biondo Investment Advisors, LLC 265,840$4,203,0000.72%
EAM Global Investors LLC 157,065$2,483,0000.69%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders